DENTSPLY SIRONA Inc (NASDAQ: XRAY) received a Hold rating from Barrington analyst Michael Petusky today. The company’s shares closed yesterday at $40.39, close to its 52-week low of $38.83.
Petusky wrote:
“We are cutting our investment rating to MARKET PERFORM in response to XRAY’s weak financial guidance for the remainder of FY/18 and the massive uncertainty we still see surrounding this business beyond this year. This update marks a new low in DENTSPLY SIRONA’s disappointing 2 ½ year history as a combined publicly-traded company.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 15.3% and a 58.9% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
The word on The Street in general, suggests a Hold analyst consensus rating for DENTSPLY SIRONA Inc with a $44 average price target, representing an 9.0% upside. In a report issued on August 7, Robert W. Baird also downgraded the stock to Hold with a $38 price target.
.
See today’s analyst top recommended stocks >>
Based on DENTSPLY SIRONA Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1.12 billion. In comparison, last year the company had a GAAP net loss of $1.05 billion.
Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2018, Michael J. Coleman, a Director at XRAY sold 6,038 shares for a total of $265,503.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DENTSPLY SIRONA, Inc. engages in the design, manufacture, sales, and distribution of professional dental products and technologies. It operates through the Technologies and Equipment and Consumables segments.
